BELLICUM PHARMACEUTICALS, INC·4

Jan 4, 4:02 PM ET

Naeve Gregory S. 4

4 · BELLICUM PHARMACEUTICALS, INC · Filed Jan 4, 2018

Insider Transaction Report

Form 4
Period: 2018-01-02
Naeve Gregory S.
Sr. VP, Chief Business Officer
Transactions
  • Award

    Employee Stock Option (right to buy)

    2018-01-02+14,62514,625 total
    Exercise: $9.23Exp: 2028-01-01Common Stock (14,625 underlying)
  • Award

    Restricted Stock Units

    2018-01-02+8,1258,125 total
    Common Stock (8,125 underlying)
Footnotes (3)
  • [F1]25% of the shares subject to the stock option vest and become exercisable on January 2, 2019, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
  • [F2]Each restricted stock unit represents a contingent right to receive one share of BLCM common stock.
  • [F3]The restricted stock units vest in four equal annual installments beginning January 2, 2019.

Documents

1 file
  • 4
    wf-form4_151509973969080.xmlPrimary

    FORM 4